%0 Journal Article %A Alexander Karaivanov %A Dongwoo Kim %A Shih En Lu %A Hitoshi Shigeoka %T COVID-19 Vaccination Mandates and Vaccine Uptake %D 2022 %R 10.1101/2021.10.21.21265355 %J medRxiv %P 2021.10.21.21265355 %X We evaluate the impact of government-mandated proof of vaccination requirements for access to public venues and non-essential businesses on COVID-19 vaccine uptake. We find that the announcement of a mandate is associated with a rapid and significant surge in new vaccinations (more than 60% increase in weekly first doses), using the variation in the timing of these measures across Canadian provinces in a difference-in-differences approach. Time-series analysis for each province and for France, Italy and Germany corroborates this finding. Counterfactual simulations using our estimates suggest the following cumulative gains in the vaccination rate among the eligible population (age 12 and over) as of October 31, 2021: up to 5 percentage points (p.p.) (90% CI 3.9–5.8) for Canadian provinces, adding up to 979,000 (425,000-1,266,000) first doses in total for Canada (5 to 13 weeks after the provincial mandate announcements), 8 p.p. (4.3–11) for France (16 weeks post-announcement), 12 p.p. (5–15) for Italy (14 weeks post-announcement) and 4.7 p.p. (4.1–5.1) for Germany (11 weeks post-announcement).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding external to the authors' home institution was received for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in this manuscript is based on information available in public domain. Data sources and links are provided within the manuscript.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this manuscript is based on information available in public domain. Data sources and links are provided within the manuscript. %U https://www.medrxiv.org/content/medrxiv/early/2022/04/11/2021.10.21.21265355.full.pdf